Melanoma & Skin Cancers

Quick Links
NewsMore ›

FDA approves nivolumab-ipilimumab combination for melanoma
Nivolumab, a programmed death receptor-1 (PD-1)–blocking antibody, has been approved for use in combination with ipilimumab for treating people with BRAF V600 wild-type,... More »

Topical fluorouracil shows long-term benefit for actinic keratoses
One course of topical fluorouracil cream reduced the need for localized treatments and the number of actinic keratoses (AK) over a mean follow-up of 2.6 years in the Veterans... More »

Dr. Claus Garbe

Melanoma regression a positive prognostic indicator
Histologic regression in melanoma is associated with a significantly lower risk of sentinel lymph node positivity and may serve as a prognostic factor when deciding whether... More »

CommentaryMore ›
Dr. Gideon Blumenthal

Immune-related patterns of response present challenges
With the race to develop cancer immunotherapies escalating and new agents appearing in the clinic, oncologists’ decision-making toolbox will need to evolve. “As... More »

Point/Counterpoint: What is the first-line treatment of choice for metastatic BRAF-mutant melanoma?
Dr. Mario Sznol and Dr. Jeffrey Sosman debate immunotherapy vs. BRAF-targeted therapy.

Mini X-Ray Device Treats Nonmelanoma Skin Cancers
MIAMI BEACH – An x-ray tube about the size of a sewing needle can safely deliver radiation to nonmelanoma skin tumors on the nose, scalp, or other highly visible areas of... More »

  VideoMore ›

VIDEO: Dual immunotherapy more powerful in melanoma, but where do we go from here?
CHICAGO – Combining the immunotherapy antibodies nivolumab and ipilimumab induced more robust responses in untreated advanced melanoma when used together than as single... More »

VIDEO: Lymphadenectomies don’t boost survival in melanoma with SLN micrometastases
CHICAGO – Complete lymph node dissection did not improve survival in a prospective, randomized trial of 483 patients with stage III melanoma and micrometastases in their... More »

VIDEO: Updating the immune response to nonmelanoma skin cancer
ASHEVILLE, N.C. – Recent advances in basic science have shown how the local immune environment in tissue surrounding nonmelanoma skin cancer compares to adjacent normal... More »